Business Context and Reporting Period
Aimei Health Technology Co., Ltd. (AFJK) is a Cayman Islands exempted company and a "blank check" SPAC formed to pursue a business combination with healthcare innovation targets. The filing covers the quarterly period ended March 31, 2026. The Company has not yet commenced operations; its activities are limited to organizational costs and pursuing a merger with United Hydrogen Group Inc., a transaction approved by shareholders in November 2025 but currently pending regulatory approval from the China Securities Regulatory Commission (CSRC).
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Income | $45,440 | $184,662 |
| Operating Costs | $(61,984) | $(413,414) |
| Interest Income (Trust) | $107,424 | $598,076 |
| Cash (Operating) | $18,516 | $7,345 |
| Cash (Trust Account) | $12,276,196 | $12,100,110 |
| Total Assets | $12,294,903 | $12,103,039 |
| Total Liabilities | $4,208,084 | $4,061,660 |
| Working Capital Deficit | $(3,499,377) | Not explicitly stated |
| Extension Loans (Related Party) | $2,092,724 | $2,024,062 |
Material Changes vs. Prior Period
- Net Income Decline: Net income decreased to $45,440 from $184,662 in Q1 2025. This was primarily driven by a significant drop in interest income earned on the Trust Account ($107,424 vs. $598,076), reflecting lower interest rates or principal balances compared to the prior year.
- Cost Reduction: General, administrative, and operational costs decreased substantially to $61,984 from $413,414 in the prior year.
- Share Redemptions: No shares were redeemed during Q1 2026. However, significant redemptions occurred in late 2025 (approx. 2.95 million shares in November 2025), reducing the number of public shares subject to redemption to 1,040,332 as of March 31, 2026.
- Extension Payments: The Company continued to fund monthly extension payments into the Trust Account via related-party loans to extend the deadline for consummating the business combination.
Outlook, Risks, and Management Commentary
- Merger Status: The proposed business combination with United Hydrogen is expected to close in late 2026, subject to CSRC approval. The Company has extended its combination deadline multiple times, with the current deadline set for July 6, 2026.
- Liquidity and Going Concern: The Company has a working capital deficit of approximately $3.5 million. Management has raised substantial doubt about the Company's ability to continue as a going concern if the business combination is not consummated by the deadline. Liquidity is currently supported by related-party extension loans and minimal operating cash.
- Related Party Dependence: The Company relies on the Sponsor and United Hydrogen for extension loans (currently totaling over $2 million) to maintain the Trust Account balance and extend the merger timeline.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2026.
Investor Verification Checklist
- CSRC Approval Status: Verify the current status of the China Securities Regulatory Commission review for United Hydrogen, as this is the primary blocker to closing the merger.
- Extension Deadline: Confirm the exact remaining time to the July 6, 2026 deadline and the sufficiency of funds in the Trust Account to cover potential redemptions or liquidation.
- Related Party Loans: Review the terms of the $2.09 million in extension loans and the $989,801 due to related companies to understand potential dilution or repayment obligations upon closing.
- Internal Control Remediation: Assess the specific deficiencies in disclosure controls and the plan to remediate them, given the "not effective" conclusion.
- Redemption Risk: Monitor for any new shareholder redemption activity as the July 2026 deadline approaches, which could further deplete the Trust Account.